Tumor-derived exosomes: a new source of tumor rejection antigens.
暂无分享,去创建一个
L. Zitvogel | N. Chaput | F. André | G. Raposo | S. Amigorena | C. Flament | E. Angevin | L Zitvogel | G Raposo | F André | N E C Schartz | N Chaput | C Flament | S Amigorena | E Angevin | N. Schartz | N. Schartz | Graça Raposo | Sebastian Amigorena | Fabrice André | Sebastian Amigorena | Eric Angevin | Laurence Zitvogel
[1] Laurence Zitvogel,et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.
[2] Keiko Miwa,et al. Identification of a factor that links apoptotic cells to phagocytes , 2002, Nature.
[3] J. Sixma,et al. Activated Platelets Release Two Types of Membrane Vesicles: Microvesicles by Surface Shedding and Exosomes Derived From Exocytosis of Multivesicular Bodies and -Granules , 1999 .
[4] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Gilboa,et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.
[6] P. Romero,et al. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway , 2000, Nature Immunology.
[7] S. Akira,et al. A Toll-like receptor recognizes bacterial DNA , 2000, Nature.
[8] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[9] Laurence Zitvogel,et al. Molecular Characterization of Dendritic Cell-Derived Exosomes , 1999, The Journal of cell biology.
[10] R. Steinman,et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. , 2001, Cancer research.
[11] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[12] Osamu Takeuchi,et al. Maturation of Human Dendritic Cells by Cell Wall Skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Involvement of Toll-Like Receptors , 2000, Infection and Immunity.
[13] L. Zitvogel,et al. Malignant effusions and immunogenic tumour-derived exosomes , 2002, The Lancet.
[14] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[15] M. Hanna,et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Laurence Zitvogel,et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.
[17] C. Melief,et al. B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.
[18] A. Mason,et al. Exosome formation during maturation of mammalian and avian reticulocytes: Evidence that exosome release is a major route for externalization of obsolete membrane proteins , 1991, Journal of cellular physiology.
[19] B. Lieubeau,et al. Role of Antigen-Presenting Cells in Long-Term Antitumor Response Based on Tumor-Derived Apoptotic Body Vaccination , 2000, Pathobiology.
[20] Jonathan J. Lewis,et al. Immunization of cancer patients with autologous cancer‐derived heat shock protein gp96 preparations: A pilot study , 2000, International journal of cancer.
[21] M. Hanna,et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.